These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 17954725)

  • 1. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.
    Pichyangkul S; Kum-Arb U; Yongvanitchit K; Limsalakpetch A; Gettayacamin M; Lanar DE; Ware LA; Stewart VA; Heppner DG; Mettens P; Cohen JD; Ballou WR; Fukuda MM
    Infect Immun; 2008 Jan; 76(1):229-38. PubMed ID: 17954725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
    Spring MD; Cummings JF; Ockenhouse CF; Dutta S; Reidler R; Angov E; Bergmann-Leitner E; Stewart VA; Bittner S; Juompan L; Kortepeter MG; Nielsen R; Krzych U; Tierney E; Ware LA; Dowler M; Hermsen CC; Sauerwein RW; de Vlas SJ; Ofori-Anyinam O; Lanar DE; Williams JL; Kester KE; Tucker K; Shi M; Malkin E; Long C; Diggs CL; Soisson L; Dubois MC; Ballou WR; Cohen J; Heppner DG
    PLoS One; 2009; 4(4):e5254. PubMed ID: 19390585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A.
    Brando C; Ware LA; Freyberger H; Kathcart A; Barbosa A; Cayphas S; Demoitie MA; Mettens P; Heppner DG; Lanar DE
    Infect Immun; 2007 Feb; 75(2):838-45. PubMed ID: 17101665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
    Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
    J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
    Stewart VA; McGrath SM; Walsh DS; Davis S; Hess AS; Ware LA; Kester KE; Cummings JF; Burge JR; Voss G; Delchambre M; Garçon N; Tang DB; Cohen JD; Heppner DG
    Vaccine; 2006 Oct; 24(42-43):6483-92. PubMed ID: 16904798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
    Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
    Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
    Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.
    Pichyangkul S; Tongtawe P; Kum-Arb U; Yongvanitchit K; Gettayacamin M; Hollingdale MR; Limsalakpetch A; Stewart VA; Lanar DE; Dutta S; Angov E; Ware LA; Bergmann-Leitner ES; House B; Voss G; Dubois MC; Cohen JD; Fukuda MM; Heppner DG; Miller RS
    Vaccine; 2009 Dec; 28(2):452-62. PubMed ID: 19857448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen.
    Mettens P; Dubois PM; Demoitié MA; Bayat B; Donner MN; Bourguignon P; Stewart VA; Heppner DG; Garçon N; Cohen J
    Vaccine; 2008 Feb; 26(8):1072-82. PubMed ID: 18258343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.
    Tewari K; Flynn BJ; Boscardin SB; Kastenmueller K; Salazar AM; Anderson CA; Soundarapandian V; Ahumada A; Keler T; Hoffman SL; Nussenzweig MC; Steinman RM; Seder RA
    Vaccine; 2010 Oct; 28(45):7256-66. PubMed ID: 20846528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.
    Stewart VA; McGrath SM; Dubois PM; Pau MG; Mettens P; Shott J; Cobb M; Burge JR; Larson D; Ware LA; Demoitie MA; Weverling GJ; Bayat B; Custers JH; Dubois MC; Cohen J; Goudsmit J; Heppner DG
    Infect Immun; 2007 May; 75(5):2283-90. PubMed ID: 17307942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.
    Walsh DS; Pichyangkul S; Gettayacamin M; Tongtawe P; Siegrist CA; Hansukjariya P; Kester KE; Holland CA; Voss G; Cohen J; Stewart AV; Miller RS; Ballou WR; Heppner DG
    Am J Trop Med Hyg; 2004 May; 70(5):499-509. PubMed ID: 15155981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).
    Cawlfield A; Genito CJ; Beck Z; Bergmann-Leitner ES; Bitzer AA; Soto K; Zou X; Hadiwidjojo SH; Gerbasi RV; Mullins AB; Noe A; Waters NC; Alving CR; Matyas GR; Dutta S
    Vaccine; 2019 Jun; 37(29):3793-3803. PubMed ID: 31151801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.
    Pichyangkul S; Gettayacamin M; Miller RS; Lyon JA; Angov E; Tongtawe P; Ruble DL; Heppner DG; Kester KE; Ballou WR; Diggs CL; Voss G; Cohen JD; Walsh DS
    Vaccine; 2004 Sep; 22(29-30):3831-40. PubMed ID: 15364429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.
    Stewart VA; Walsh DS; McGrath SM; Kester KE; Cummings JF; Voss G; Delchambre M; Garçon N; Cohen JD; Heppner DG
    Vaccine; 2006 Oct; 24(42-43):6493-502. PubMed ID: 16911849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein/AS01
    Nielsen CM; Ogbe A; Pedroza-Pacheco I; Doeleman SE; Chen Y; Silk SE; Barrett JR; Elias SC; Miura K; Diouf A; Bardelli M; Dabbs RA; Barfod L; Long CA; Haynes BF; Payne RO; Minassian AM; Bradley T; Draper SJ; Borrow P
    Cell Rep Med; 2021 Mar; 2(3):100207. PubMed ID: 33763653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates.
    Padte NN; Boente-Carrera M; Andrews CD; McManus J; Grasperge BF; Gettie A; Coelho-dos-Reis JG; Li X; Wu D; Bruder JT; Sedegah M; Patterson N; Richie TL; Wong CH; Ho DD; Vasan S; Tsuji M
    PLoS One; 2013; 8(10):e78407. PubMed ID: 24205224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.
    Ockenhouse CF; Angov E; Kester KE; Diggs C; Soisson L; Cummings JF; Stewart AV; Palmer DR; Mahajan B; Krzych U; Tornieporth N; Delchambre M; Vanhandenhove M; Ofori-Anyinam O; Cohen J; Lyon JA; Heppner DG;
    Vaccine; 2006 Apr; 24(15):3009-17. PubMed ID: 16356603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin.
    Martin ML; Bitzer AA; Schrader A; Bergmann-Leitner ES; Soto K; Zou X; Beck Z; Matyas GR; Dutta S
    Malar J; 2019 Nov; 18(1):377. PubMed ID: 31775762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.